Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2394-2404

  Nebbioso, Angela ^a   Pereira, Raquel ^d   Khanwalkar, Harshal ^e,g   Matarese, Filomena ^f   García Rodríguez, José ^d   Miceli, Marco ^a   Logie, Colin ^f   Kedinger, Valerie ^e,h   Ferrara, Felicetto ^c   Stunnenberg, Hendrik G ^f   De Lera, Angel R ^d   Gronemeyer, Hinrich ^e   Altucci, Lucia ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

^d UNIVERSITY OF VIGO   (Spain)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^g LUPIN LIMITED   (India)

^h Polyplus transfection   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; HISTONE DEACETYLASE; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIRTUIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UVI 5008;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL STRAIN K 562; CELL STRAIN MCF 7; CELL STRAIN U937; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LEUKEMIA CELL; MELANOMA CELL; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DISULFIDES; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; HCT116 CELLS; HL-60 CELLS; HUMANS; K562 CELLS; MICE; MICE, NUDE; OXIMES; REACTIVE OXYGEN SPECIES; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355166904     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0525     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010;17:173-85.
3. Martens JH, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 2010;584:2662-9.
4. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-8. (Pubitemid 28099683)
5. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H, RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810. (Pubitemid 47504871)
6. Matsushita H, Scaglioni PP, Bhaumik M, Rego EM, Cai LF, Majid SM, et al. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 2006;203:821-8.
7. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6:107-16. (Pubitemid 43361543)
8. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
9. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
10. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, MichonAM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29:255-65.
11. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010;10:457-69.
12. Szyf M. Epigenetics, DNA methylation and chromatin modifying drugs. Ann Rev Pharmacol Toxicol 2009;49:243-63.
13. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41:199-213.
14. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
15. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. (Pubitemid 44348499)
16. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587-91.
17. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612-8. (Pubitemid 47105506)
18. Ooi SK, Bestor TH. The colorful history of active DNA demethylation. Cell 2008;133:1145-8. (Pubitemid 351852922)
19. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6. (Pubitemid 40215840)
20. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84. (Pubitemid 40215841)
21. Nebbioso A, Manzo F, Miceli M, Conte M, Manente L, Baldi A, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 2009;10:776-82.
22. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A 2007;104:17335-40. (Pubitemid 350219843)
23. Denissov S, van Driel M, Voit R, Hekkelman M, Hulsen T, Hernandez N, et al. Identification of novel functional TBP-binding sites and general factor repertoires. EMBO J 2007;26:944-54.
24. Akkers RC, van Heeringen SJ, Jacobi UG, Janssen-Megens EM, Francoijs KJ, Stunnenberg HG, et al. A hierarchy of H3K4me3 and H3K27me3 acquisition in spatial gene regulation in Xenopus embryos. Dev Cell 2009;17:425-34.
25. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG. Whole-genome DNA methylation profiling using MethylCap-seq. Methods 2010;52:232-6.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
27. Piña IC, Gautschi JT, Wang GYS, Sanders ML, Schmitz FJ, France D, et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003;68:3866-73. (Pubitemid 36576636)
28. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305-11. (Pubitemid 40994416)
29. Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 2009;69:4277-85.
30. Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008;108:27-33. (Pubitemid 350299431)
31. Garcia J, Franci G, Pereira R, Benedetti R, Nebbioso A, Rodriguez-Barrios F, et al. Epigenetic profiling of the antitumor natural product psammaplin Aand its analogues. BioorgMedChem2011;19:3637-49.
32. Maas NL, Miller KM, DeFazio LG, Toczyski DP. Cell cycle and checkpoint regulation of histone H3 K56 acetylation by Hst3 and Hst4. Mol Cell 2006;23:109-19. (Pubitemid 43963450)
33. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009;459:113-7.
34. Ozdemir A, Spicuglia S, Lasonder E, Vermeulen M, Campsteijn C, Stunnenberg HG, et al. Characterization of lysine 56 of histone H3 as an acetylation site in Saccharomyces cerevisiae. J Biol Chem 2005; 280:25949-52. (Pubitemid 41022184)
35. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26. (Pubitemid 351636297)
36. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, Wolberger C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell 2002;10:523-35. (Pubitemid 35291068)
37. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006;26:28-38.
38. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-6. (Pubitemid 38182673)
39. Bai YX, Yi JL, Li JF, Sui H. Clinicopathologic significance of BAG1 and TIMP3 expression in colon carcinoma. World J Gastroenterol 2007;13:3883-5. (Pubitemid 47272318)
40. Durr ML, Mydlarz WK, Shao C, Zahurak ML, Chuang AY, Hoque MO, et al. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One 2010;5:e10828.
41. Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009;58: 2396-401.
42. Zhang Y, Adachi M, Kawamura R, Imai K.BMFis a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006;13:129-40.
43. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004;13:627-38. (Pubitemid 38368121)
44. Lee MW, Park SC, Kim JH, Kim IK, Han KS, Kim KY, et al. The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett 2002;182:75-82. (Pubitemid 34518659)
45. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004;116:551-63. (Pubitemid 38264432)
46. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-5. (Pubitemid 38393275)
47. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004; 279:28873-9. (Pubitemid 38915754)
48. Myatt SS, Brosens JJ, Lam EW. Sense and sensitivity: FOXO and ROS in cancer development and treatment. Antioxid Redox Signal 2011;14: 675-87.
49. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28. (Pubitemid 34587077)
50. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6. (Pubitemid 44835126)